In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced fluorescence capillary gel electrophoresis.
Mastering these methods and CQAs is vital for drug developers looking to navigate the development pipeline with confidence and achieve clinical success. By incorporating advanced characterization data into your strategies, you can optimize formulations and troubleshoot potential issues earlier than ever before.
- Unlock Essential Insights: Learn how to identify and measure critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs), empowering you to enhance drug efficacy and safety from the start.
- Master Cutting-Edge Techniques: Gain hands-on knowledge of advanced analytical methods like nanopore sequencing, mass spectrometry, and more, equipping you with the tools to streamline your development process and ensure robust product quality.
- Optimize Your Development Strategy: Discover how integrating advanced characterization data allows you to troubleshoot potential issues early, reducing delays and accelerating your journey to clinical success.
CASE STUDY
Join us to discover how mRNA quality and advanced analytics are key players in the successful development of mRNA-based therapeutics—featuring this compelling case study.
mRNA and LNP Analytical Services
Rapidly and confidently measure critical quality attributes (CQAs) across all stages of drug development—from discovery to clinical trials—with our mRNA and LNP Analytical Services. To meet the unique demands of mRNA drug discovery and development, Vernal provides both standardized and tailored analytical methods.
